REFERENCES
- Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437–55.
- Realdi G, Alberti A, Rugge M, Rigoli AM, Tremolada F, Shcivazappa L, et al. Long-term follow-up of acute and chronic non A non B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut 1982; 23: 270–5.
- Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of Interferon-α 2b. Hepatology 1993; 18: 1300–5.
- Chemello L, Bonetti P, Crivalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of interferon-α 2 a in chronic hepatitis C. Hepatology 1995; 22: 700–6.
- Sidwell RW, Robins RK, Hillary IW. Ribavirin: an antiviral agent. Pharmacol Ther 1977; 6: 123–46.
- Reichard OR, Andersson J, Schwarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058–61.
- Camps Joan, García Nicolás, Riezn-Boj Jose I, Civeira Maria P, Prieto Jesús. Ribavirin in the treatment of chronic hepatitis C unresponsive to inerferon α. J Hepatol 1993; 19: 408–12.
- Schwarcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon-α 2b and Ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995; 23 (Suppl 2): 17–21.
- Brouwer J, Nevens F, Michielson P. What options are when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon. J Hepatol 1994; 21: 17A.
- Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: a meta-analysis of individual patient data from European centers. J Hepatol 1997; 26: 961–6.
- Bellobuono A, Mondazi L, Tempini S, Sillni A, Vicari F, Idéo G. Ribavirin and interferon α combination therapy vs. Interferon α alone in the retreatment of chronic hepatitis C: to randomized clinice trial. J Viral Hepat 1997; 4: 185–91.
- Davis G, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, et al., for the International Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with Ribavirin for the treatment of relapse of chronic hepatitis C. N England J Med 1998; 339: 1493–9.
- Reichard O, Norkans G, Fridén A, Braconier JH, Sonnerborg A, Weiland O, for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon-α 2b without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83–7.
- Poynard T, Marcellin P, Lee SS, Niederan C, Minuk G, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J, et al., for the International Hepatitis Interventional Therapy Group. Randomised trial of interferon-α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32.
- McHutchison J, Gordon S, Schiff E, Shiffman ML, Lee W, Rustgi V, Goodman Z, Ling M, Cort S, Albrecht J, et al., for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92.
- Vandelli C, Renzo F, Lovato E, Sardini C, Di Marco G, Tisminetzky S, et al. Interferon versus Ribavirin plus interferon in chronic hepatitis C patients relapsers and non responders to recombinant interferon. J Hepatol 1998; 28 (Suppl 1): 120.
- De Bac C, Pastore G, Piccinino F, Badolato MC, Tosti ME, Oso A, et al. Ribavirin and interferon retreatment of HVC chronic patients non to respond to interferon. J Hepatol 1998; 28 (Suppl 1): 123.